For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.
For this indication, competent medicine agencies globally authorize below treatments:
10 - 12 mg per m² of body surface area (BSA)
From 10 To 12 mg per m² of body surface area (BSA) once every day for 3 day(s)
10-12 mg/m² i.v. daily for 3 days in combination with cytarabine.